Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma.

Cancers (Basel) · 2023 · PMC9913409 · PMID 36765821

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the OS was better in patients treated with pembrolizumab, the improvement did not reach statistical significance, probably due to the 60% crossover rate reported in the intention-to-treat (ITT) population [ 23 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.